<DOC>
	<DOCNO>NCT00881205</DOCNO>
	<brief_summary>This study evaluate efficacy safety 10 cm² rivastigmine patch vs. placebo cognitively impaired Multiple Sclerosis ( MS ) patient . Primary objective assessment cognition Selective Reminding Test ( SRT ) -a subtest brief repeatable battery ( BRB ) - titration 4 week maintenance 12 week . This double-blind period follow 52-week open-label treatment phase assess long-term safety rivastigmine patch patient .</brief_summary>
	<brief_title>Rivastigmine Multiple Sclerosis Patients With Cognitive Impairment</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<criteria>1 . Written inform consent participate trial 2 . Males females 18 55 year age ; 3 . Definite diagnosis multiple sclerosis define 2005 revise McDonald criterion 4 . MSsubtype : Clinical isolated syndrome ( CIS ) , Relapsing Remitting Multiple Sclerosis ( RRMS ) , Secondary progressive Multiple Sclerosis ( SPMS ) ; 5 . Cognitive Impairment 6 . Sufficient education read , write communicate comprehensibly 1 . Use investigational drug time enrollment , within 30 day 5 halflives enrollment , whichever longer 2 . Women pregnant breast feed menstruate capable become pregnant practice medically approve method contraception 3 . With physical sensory disability subjectively prevent patient complete study requirement 4 . Patients suffer type concomitant psychiatric and/or neurological disorder MS know affect cognition ( e.g . severe depressive symptom , cerebrovascular disease , epilepsy ) . 5 . Patients suffer acute relapse MS previous 30 day ( treat intravenous oral glucocorticoid regimen ) prior baseline . 6 . With history current problem drugaddiction and/or alcohol abuse . 7 . Known 'new ' diagnosis diabetes mellitus ( screen blood glucose suspicious diabetes [ ≥126 mg/dL ≥7 mmol/L fast ≥200 mg/dL 11.1 mmol/L random test ] patient evaluate diabetes mellitus ) 8 . With history severe moderatesevere cranioencephalic trauma . 9 . History presence intolerance contraindication application rivastigmine ( drug similar chemical structure ) list current Investigator 's Brochure and/or SPC , i.e . severe liver insufficiency , pancreatitis , gastric ulcer , convulsion . 10 . With history past year current diagnosis cerebrovascular disease ( instance , stroke , transient ischemic event , aneurysm ) . 11 . Severe depressive symptom indicate score ≥ 14 MADRS screen 12 . History malignancy organ system , treat untreated , within past 5 year whether evidence local recurrence metastasis , exception localize basal cell carcinoma skin Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Cognition</keyword>
	<keyword>Rivastigmine</keyword>
	<keyword>Patch</keyword>
</DOC>